<DOC>
	<DOCNO>NCT00584818</DOCNO>
	<brief_summary>The purpose study determine dose PB127 detection and/or exclusion coronary artery disease use cardiac ultrasound . This study also evaluate safety PB127 .</brief_summary>
	<brief_title>Dose Finding Study PB127 Ultrasound Contrast Agent Healthy Volunteers Patients With Coronary Artery Disease</brief_title>
	<detailed_description />
	<mesh_term>Coronary Artery Disease</mesh_term>
	<mesh_term>Myocardial Ischemia</mesh_term>
	<mesh_term>Coronary Disease</mesh_term>
	<criteria>Stages 1 2 1 . Men woman 2 . Ages 18 30 3 . Normal volunteer 4 . No history ( suspicion ) CAD Stage 3 1 . Men woman know suspected CAD 2 . Ages 18 year old 3 . Scheduled undergone clinically indicated coronary angiography within 28 day prior follow Study Day 1 1 . Coronary angiography within 28 day prior Study Day 1 and/or SPECT must noninterventional 2 . Coronary angiography image available digital format ( non cine ) transmission core laboratory 4 . Scheduled undergone SPECT within 28 day prior follow Study Day 1 1 . Unable provide write informed consent 2 . Women pregnant lactate 3 . Known hypersensitivity know contraindication : 1 . Dipyridamole 2 . Ultrasound contrast agent ( include PB127 excipients ) 3 . Blood , blood product , albumin , egg white , protein 4 . Use caffeine xanthine containing product within 24 hour prior PB127 administration Study Day 1 ( Stages 2 3 ) 5 . Previous exposure PB127 6 . Inadequate echocardiographic windows 7 . Heart transplant 8 . Known right left shunt , include atrial septal defect 9 . History CABG 10 . Current uncontrolled ventricular tachycardia , atrial fibrillation , atrial tachycardia , atrial flutter 11 . Pacemaker defibrillator 12 . Unstable angina grade CCS Class IV severity ongoing symptom and/or ongoing infusion IV nitroglycerin 13 . Second degree great heart block 14 . Hypertension ( SPB &gt; 200 and/or DBP &gt; 110 mmHg two consecutive reading within 1 hour prior PB127 administration ) 15 . Hypotension ( SPB &lt; 90 mmHg two consecutive reading within 1 hour prior PB127 administration ) 16 . Severe aortic stenosis ( &gt; 100 mmHg peak transvalvar gradient &lt; 0.6 cm2 estimate valve area ) 17 . Pulmonary edema within 7 day prior Study Day 1 18 . Resting oxygen saturation le 90 % 19 . Q wave MI major surgery within 7 day prior Study Day 1 20 . PTCA within 28 day prior Study Day 1 21 . Chronic obstructive pulmonary disease bronchospastic airway disease , opinion Investigator , significant enough contraindicate dipyridamole 22 . Known history severe pulmonary hypertension characterize estimate pulmonary artery systolic pressure &gt; 50 mmHg 23 . Liver disease , characterize include one follow 1 . Elevated total bilirubin &gt; upper limit normal 2 . Currently elevate hepatic enzyme &gt; 3X upper limit normal 24 . Medical condition circumstance would significantly decrease chance obtain reliable data achieve study objective ( i.e. , drug dependence , psychiatric disorder , dementia , associate illness ) ; extenuate circumstance medical condition make unlikely patient complete clinical trial follow evaluation ; reason expect poor compliance clinical investigator 's instruction</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>April 2008</verification_date>
	<keyword>coronary artery disease</keyword>
	<keyword>chest pain</keyword>
	<keyword>healthy volunteer</keyword>
	<keyword>SPECT</keyword>
	<keyword>angiogram</keyword>
	<keyword>ultrasound</keyword>
	<keyword>echocardiogram</keyword>
	<keyword>perfusion</keyword>
</DOC>